Do Caregivers Value the New Antiamyloid Treatments for Alzheimer's Disease More Than Home-Based Care?
Authors:
- 26 November 2024
- journal article
- Published by Elsevier in The American Journal of Geriatric Psychiatry
- Vol. 33 (4) , 438-449
Abstract
No abstract availableKeywords
Funding Information
- National Institutes of Health
This publication has 37 references indexed in Scilit:
- Mindfulness Processes that Mitigate COVID-Related Stressors in Caregivers in the United StatesJournal of Child and Family Studies, 2023
- Are New Alzheimer Drugs Better Than Older Drugs?JAMA Internal Medicine, 2023
- Ushering in a New Era of Alzheimer Disease TherapyJAMA, 2023
- Donanemab in Early Symptomatic Alzheimer DiseaseJAMA, 2023
- Novel Alzheimer Disease Treatments and Reconsideration of US Pharmaceutical Reimbursement PolicyJAMA, 2023
- Donanemab for Alzheimer Disease—Who Benefits and Who Is Harmed?JAMA, 2023
- Public perspective on medications to delay Alzheimer's disease symptomsJournal of Genetic Counseling, 2023
- Anti-Amyloid Monoclonal Antibodies are Transformative Treatments that Redefine Alzheimer's Disease TherapeuticsDrugs, 2023
- Treatment Preference for Alzheimer’s Disease: A Multicriteria Decision Analysis with Caregivers, Neurologists, and PayorsNeurology and Therapy, 2022
- Health Policy and DementiaCurrent Psychiatry Reports, 2018